Visualitza per autor "Ciardiello, Fortunato"
Ara mostrant els elements 1-5 d 5
-
Cetuximab every 2 weeks versus standard weekly dosing administration schedule
Bokemeyer, Carsten; Dubreuil , Olivier; GUIGAY, Joel; Kasper, Stefan; Pfeiffer, Per; Ciardiello, Fortunato; Tabernero, Josep (Future Medicine, 2024-03) -
Clinical management of metastatic colorectal cancer in the era of precision medicine
Ciardiello, Davide; Martini, Giulia; Napolitano, Stefania; Tabernero Caturla, Josep; Cervantes, Andrés; Ciardiello, Fortunato (Wiley, 2022-07) -
Impact of KRASG12 mutations on survival with trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer: post hoc analysis of the phase III SUNLIGHT trial
Fakih, Marwan; Prager, M.D., Gerald; Van Cutsem, Eric; Tabernero, Josep; taieb, julien; Ciardiello, Fortunato (Elsevier, 2024-03) -
The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer
Ciardiello, Fortunato; Hirsch, Fred R.; Pirker, Robert; Valencia, Christian; Smit, Egbert; FELIP, ENRIQUETA (Elsevier, 2024-01) -
Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design
Tabernero Caturla, Josep; Prager, Gerald W; Leger, Catherine; Fakih, Marwan; Taieb, Julien; Ciardiello, Fortunato (Future Medicine, 2021-06)